摘要:
A device for distributing, mixing, injecting, and/or removing several fluids, one of the fluids being a main fluid A.sub.1, and at least a first secondary fluid B.sub.1 and a second secondary fluid B.sub.2, said device having means (3, 4) for collecting said main fluid A.sub.1, said collecting means being related to at least one mixing chamber having at least one wall substantially parallel to the device axis circuit (12, 5) of a first secondary fluid B.sub.1, and at least a second injection and/or removal circuit (13, 6) of a second secondary fluid B.sub.2, said injection and/or removal circuits being in communication with the mixing chamber (7) by means of one or more openings (15, 16) allowing passage of said secondary fluids B.sub.1 and B.sub.2 to or from said mixing chamber (7), said mixing chamber (7) having at least one inlet orifice (14) for the main fluid, at least one outlet orifice (17), and means (8, 9) for redistributing the fluid coming from the mixing chamber, with said injection and/or extraction circuits being separated and disposed in the vicinity of said mixing chamber according to at least one of the walls of said chamber whose direction is substantially parallel to the device axis.
摘要:
The invention relates to a compound selected from those of formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and X are as defined in the description and medicinal product containing the same useful for treating a disorder of the melatoninergic system.
摘要:
A method of treating a mammal afflicted with a disorder associated with the Na.sup.+ -independent Cl.sup.- /HCO.sub.3 - exchanger comprising the step of administering a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and n are as defined in the description, which is effective for alleviating the said disorder.
摘要:
The invention relates to a compound selected from those of formula (I): ##STR1## in which Ar, X, R.sub.1 and R.sub.2 are as defined in the description and a medicinal product containing the same in order to treat a disorder of the melatoninergic system.
摘要:
The present invention relates to a compound selected from these of formula (I): ##STR1## in which A and R.sub.1 are as defined in the description, and medicinal product containing the same which is useful for treating a disorder linked to the 5-HT.sub.3 receptors.
摘要:
The invention relates to a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.2', R.sub.2", R.sub.2'", R.sub.3 and n are as defined in the description, an optical isomer, and an addition salt thereof with a pharmaceutically-acceptable acid or base,and medicinal product containing the same useful for treating a mammal afflicted with a disorder associated to 5-HT.sub.1A or 5-HT.sub.2C receptors.
摘要:
The invention relates to a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, X and n are as defined in the description, the optical isomers thereof, and the addition salts thereof with a pharmaceutically acceptable acid or base and medicinal product containing the same, useful for treating a mammal afflicted with a pathology associated with the sigma receptors.
摘要:
A compound of formula (I): ##STR1## wherein: X represents O, S or H.sub.2,R and R' each represents hydrogen or together form a bond,R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description.useful in the treatment or prevention of disorders involving oxidative processes.
摘要:
The invention concerns a hydro treatment method in at least two stages, for a heavy hydrocarbon fraction containing asphaltenes, sulphur impurities and metallic impurities, wherein:a) in at least one first stage described as hydrodemetallization, the hydrocarbon charge and hydrogen are passed over a hydrodemetallization catalyst,b) in at least one subsequent stage described as hydrodesulphurization, the product of stage a) and hydrogen are passed over a hydrodesulphurization catalyst.The invention, in which the hydrodemetallization stage comprises one or more zones each containing hydrodemetallization catalyst operating in a fixed bed, is characterised in that this zone or these zones are preceded by two protective zones arranged in parallel, each containing a fixed bed of a hydrodemetallization catalyst, the two protective zones operating alternately.
摘要:
A compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and n are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal product containing the same for treating a mammal afflicted with a disorder connected with peroxydation processes and biosynthesis of eicosanoids.